Page last updated: 2024-10-15

3-hydroxyanthranilic acid and Epilepsy

3-hydroxyanthranilic acid has been researched along with Epilepsy in 2 studies

3-Hydroxyanthranilic Acid: An oxidation product of tryptophan metabolism. It may be a free radical scavenger and a carcinogen.
3-hydroxyanthranilic acid : An aminobenzoic acid that is benzoic acid substituted at C-2 by an amine group and at C-3 by a hydroxy group. It is an intermediate in the metabolism of the amino acid tryptophan.
3-hydroxyanthranilate : A hydroxybenzoate that is the conjugate base of 3-hydroxyanthranilic acid.

Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)

Research Excerpts

ExcerptRelevanceReference
"There was a statistically significant decrease of CSF kynurenic acid in patients with epileptic spasms compared to OND (p<0."8.12Decreased cerebrospinal fluid kynurenic acid in epileptic spasms: A biomarker of response to corticosteroids. ( Antony, J; Ardern-Holmes, S; Bandodkar, S; Dale, RC; Gill, D; Guillemin, GJ; Guller, A; Gupta, S; Han, VX; Heng, B; Innes, EA; Jones, HF; Kothur, K; Menezes, MP; Mohammad, S; Patel, S; Pires, AS; Tantsis, E; Troedson, C; Tsang, E; Webster, R; Wienholt, L; Yan, J, 2022)
"This study demonstrates decreased CSF kynurenic acid and KYNA/KYN in epileptic spasms, which may also represent a biomarker for steroid responsiveness."8.12Decreased cerebrospinal fluid kynurenic acid in epileptic spasms: A biomarker of response to corticosteroids. ( Antony, J; Ardern-Holmes, S; Bandodkar, S; Dale, RC; Gill, D; Guillemin, GJ; Guller, A; Gupta, S; Han, VX; Heng, B; Innes, EA; Jones, HF; Kothur, K; Menezes, MP; Mohammad, S; Patel, S; Pires, AS; Tantsis, E; Troedson, C; Tsang, E; Webster, R; Wienholt, L; Yan, J, 2022)
"Epileptic spasms have a diverse range of known (genetic, structural) and unknown aetiologies."5.72Decreased cerebrospinal fluid kynurenic acid in epileptic spasms: A biomarker of response to corticosteroids. ( Antony, J; Ardern-Holmes, S; Bandodkar, S; Dale, RC; Gill, D; Guillemin, GJ; Guller, A; Gupta, S; Han, VX; Heng, B; Innes, EA; Jones, HF; Kothur, K; Menezes, MP; Mohammad, S; Patel, S; Pires, AS; Tantsis, E; Troedson, C; Tsang, E; Webster, R; Wienholt, L; Yan, J, 2022)
"There was a statistically significant decrease of CSF kynurenic acid in patients with epileptic spasms compared to OND (p<0."4.12Decreased cerebrospinal fluid kynurenic acid in epileptic spasms: A biomarker of response to corticosteroids. ( Antony, J; Ardern-Holmes, S; Bandodkar, S; Dale, RC; Gill, D; Guillemin, GJ; Guller, A; Gupta, S; Han, VX; Heng, B; Innes, EA; Jones, HF; Kothur, K; Menezes, MP; Mohammad, S; Patel, S; Pires, AS; Tantsis, E; Troedson, C; Tsang, E; Webster, R; Wienholt, L; Yan, J, 2022)
"This study demonstrates decreased CSF kynurenic acid and KYNA/KYN in epileptic spasms, which may also represent a biomarker for steroid responsiveness."4.12Decreased cerebrospinal fluid kynurenic acid in epileptic spasms: A biomarker of response to corticosteroids. ( Antony, J; Ardern-Holmes, S; Bandodkar, S; Dale, RC; Gill, D; Guillemin, GJ; Guller, A; Gupta, S; Han, VX; Heng, B; Innes, EA; Jones, HF; Kothur, K; Menezes, MP; Mohammad, S; Patel, S; Pires, AS; Tantsis, E; Troedson, C; Tsang, E; Webster, R; Wienholt, L; Yan, J, 2022)
"Epileptic spasms have a diverse range of known (genetic, structural) and unknown aetiologies."1.72Decreased cerebrospinal fluid kynurenic acid in epileptic spasms: A biomarker of response to corticosteroids. ( Antony, J; Ardern-Holmes, S; Bandodkar, S; Dale, RC; Gill, D; Guillemin, GJ; Guller, A; Gupta, S; Han, VX; Heng, B; Innes, EA; Jones, HF; Kothur, K; Menezes, MP; Mohammad, S; Patel, S; Pires, AS; Tantsis, E; Troedson, C; Tsang, E; Webster, R; Wienholt, L; Yan, J, 2022)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Yan, J1
Kothur, K1
Innes, EA1
Han, VX1
Jones, HF1
Patel, S1
Tsang, E1
Webster, R1
Gupta, S1
Troedson, C1
Menezes, MP1
Antony, J1
Ardern-Holmes, S1
Tantsis, E1
Mohammad, S1
Wienholt, L1
Pires, AS1
Heng, B1
Guillemin, GJ1
Guller, A1
Gill, D1
Bandodkar, S1
Dale, RC1
Muñóz-Hoyos, A1
Molina-Carballo, A1
Rodríguez-Cabezas, T1
Uberos-Fernández, J1
Ruiz-Cosano, C1
Acuña-Castroviejo, D1

Other Studies

2 other studies available for 3-hydroxyanthranilic acid and Epilepsy

ArticleYear
Decreased cerebrospinal fluid kynurenic acid in epileptic spasms: A biomarker of response to corticosteroids.
    EBioMedicine, 2022, Volume: 84

    Topics: 3-Hydroxyanthranilic Acid; Adrenal Cortex Hormones; Animals; Biomarkers; Chromatography, Liquid; Epi

2022
Relationships between methoxyindole and kynurenine pathway metabolites in plasma and urine in children suffering from febrile and epileptic seizures.
    Clinical endocrinology, 1997, Volume: 47, Issue:6

    Topics: 3-Hydroxyanthranilic Acid; Child; Child, Preschool; Circadian Rhythm; Epilepsy; Female; Humans; Infa

1997
chemdatabank.com